银芩清肺颗粒通过抑制NLRP3炎症小体介导的巨噬细胞焦亡缓解肺炎支原体肺炎
该研究探讨银芩清肺颗粒(YQQFG)治疗儿童肺炎支原体肺炎(MPP)的机制。体外实验采用MP感染的RAW264.7细胞及NLRP3过表达细胞系,体内建立MPP模型小鼠,并通过LC-MS/MS、分子对接、Western blot、ELISA及免疫荧光等方法验证。结果表明YQQFG可抑制NLRP3/Caspase-1/GSDMD通路,减少IL-1β和IL-18释放,并抑制MP外毒素,与阿奇霉素联用效果最佳。
要点
- YQQFG抑制NLRP3炎症小体介导的巨噬细胞焦亡,减轻MP诱导的急性肺损伤。
- YQQFG可降低IL-1β和IL-18释放,并抑制MP外毒素表达。
- YQQFG与阿奇霉素联用对MPP模型效果最佳,可作为儿童MPP的辅助或替代药物。
核心结论
- YQQFG通过抑制NLRP3炎症小体介导的巨噬细胞焦亡减轻炎症反应,从而改善MP诱导的急性肺损伤。
- YQQFG是儿童MPP治疗的有效辅助和替代药物。
研究设计与样本
- 体外采用MP感染的RAW264.7细胞及慢病毒构建的NLRP3过表达RAW264.7细胞系,并使用含药血清干预。
- 体内通过鼻滴注MP建立MPP模型小鼠。
- 采用LC-MS/MS鉴定YQQFG主要成分,Autodock Vina进行分子对接,CCK-8法确定含药血清干预浓度。
主要发现
- YQQFG中鉴定出25种具有良好口服生物利用度的有效成分。
- 体外和体内研究均显示YQQFG显著降低NLRP3/Caspase-1/GSDMD通路表达,减少IL-1β和IL-18释放,并抑制MP外毒素。
- 分子对接显示大多数YQQFG成分与NLRP3蛋白有强亲和力。
- 慢病毒转染和免疫荧光双染证实YQQFG显著抑制巨噬细胞中NLRP3表达,效果优于阿奇霉素(AZM)。
- YQQFG与AZM联用对MPP模型产生最佳治疗效果。
临床怎么用
- YQQFG可作为儿童MPP的辅助或替代治疗药物,尤其在与阿奇霉素联用时可能获得更优疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mycoplasma pneumoniae pneumonia (MPP) is a prevalent respiratory infectious disease in children. Given the increasing resistance of M. pneumoniae (MP) to macrolide antibiotics, the identification of new therapeutic agents is critical. Yinqin Qingfei granules (YQQFG), a Chinese patent medicine formulated specifically for pediatric MPP, lacks a clear explanation of its mechanism. METHODS: The primary components of YQQFG were identified using LC-MS/MS. In vitro, RAW264.7 cells infected with MP underwent morphological examination via scanning electron microscopy. Drug-containing serum was prepared, and its intervention concentration was determined using the CCK-8 assay. The active components of YQQFG were molecularly docked with NLRP3 protein using Autodock Vina software. A RAW264.7 cell line overexpressing NLRP3 was created using lentivirus to pinpoint the target of YQQFG. In vivo, MPP model mice were established via nasal instillation of MP. Lung damage was assessed by lung index and H&E staining. Pyroptosis-associated protein levels in cells and lung tissue were measured by western blot, while interleukin (IL)-1β and IL-18 levels in cell supernatants and mouse serum were quantified using ELISA. Immunofluorescence double staining of lung tissue sections was conducted to assess the correlation between NLRP3 protein expression and macrophages. The expression of the community-acquired respiratory distress syndrome toxin (CARDS TX) was evaluated by qPCR. RESULTS: 25 effective components with favorable oral bioavailability were identified in YQQFG. Both in vitro and in vivo studies demonstrated that YQQFG substantially reduced the expression of the NLRP3/Caspase-1/GSDMD pathway, decreasing the release of IL-1β and IL-18, and inhibited MP exotoxin. Molecular docking indicated strong affinity between most YQQFG components and NLRP3 protein. Lentivirus transfection and immunofluorescence double staining confirmed that YQQFG significantly suppressed NLRP3 expression in macrophages, outperforming azithromycin (AZM). The combination of YQQFG and AZM yielded the optimal therapeutic effect for MPP. CONCLUSION: YQQFG mitigates inflammatory responses by suppressing NLRP3 inflammasome-mediated macrophage pyroptosis, thereby ameliorating MP-induced acute lung injury. YQQFG serves as an effective adjunct and alternative medication for pediatric MPP treatment.
引用
- Song Z, Han C, Luo G, et al. Yinqin Qingfei granules alleviate Mycoplasma pneumoniae pneumonia via inhibiting NLRP3 inflammasome-mediated macrophage pyroptosis. Front Pharmacol. 2024. PMID: 39257401. doi:10.3389/fphar.2024.1437475
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。